Keyphrases
Anti-CD20
20%
Antigen Loss
20%
B-cell Lymphoma
100%
B-cell Malignancies
10%
B-cell non-Hodgkin Lymphoma (B-NHL)
10%
Biopsy Specimen
20%
Bispecific Antibody
20%
CD20
100%
CD20 Expression
100%
CD3 Bispecific
10%
Clinical Decisions
10%
Clinical Response
10%
Clinical Samples
10%
Disease Progression
10%
Extracellular Domain
10%
Immunohistochemical Staining
10%
Immunohistochemistry
10%
In Vitro Modeling
10%
Missense mutation
10%
Monotherapy
10%
Mosunetuzumab
100%
Non-Hodgkin Lymphoma
10%
Paired Biopsies
10%
Proportion of Tumour
10%
Relapsed or Refractory
100%
Resistance Mechanisms
100%
RNA Sequencing (RNA-seq)
10%
Target Antigen
20%
Targeted Agents
10%
Therapeutic Target
10%
Truncating mutation
10%
Tumor Cells
10%
Whole Exome Sequencing
10%
Immunology and Microbiology
B Cell
100%
Bispecific Antibody
12%
CD20
100%
CD3 Antigen
6%
In Vitro
6%
Missense Mutation
6%
Mosunetuzumab
100%
RNA Sequence
6%
Tumor Cell
6%
Whole Exome Sequencing
6%